Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

  • June 2025 quarter CPI no roadblock to August RBA rate cut
    June 2025 quarter CPI no roadblock to August RBA rate cut
    • News

  • Vection Secures $7.3M Defence Extension as AI Demand Strengthens
    Vection Secures $7.3M Defence Extension as AI Demand Strengthens
    • News

Little Green Pharma locks in major sales agreement with German cannabis company

  • In News
  • April 19, 2022
  • Jack Cornips
Little Green Pharma locks in major sales agreement with German cannabis company

Australian medical cannabis company Little Green Pharma (ASX: LGP) has reached a major offtake agreement with Demecan to distribute cannabis products across Germany. With the German medical cannabis market estimated to be worth €7.7bn (A$11.2bn) by 2028, this opportunity marks a massive milestone for the Company.

In July 2021, LGP acquired a world-class cultivation site in Denmark to produce 12 tonnes per annum of dried cannabis products. The development fell in line with their plans to ramp up production to meet the future market demand while white-labelling their medicines for supply into the global market. This most recent agreement has allowed the Company to offload a sizable amount of their product and guarantee sales. 

In the agreement, LGP will supply three high-THC flower strains at 450kg per annum to Demecan, with expected annual sales revenue representing €6m (A$9m). The supply agreement is secured for 3-years, where Demecan will have exclusive rights to be the first receiver of products produced by LGP.

Demecan is located in Berlin, Germany and focuses on the cultivation, importation and wholesale of medical cannabis. Having partnered with a European wholesale company, LGP is now positioned with a foot in the door for future growth opportunities around Europe. 

“The agreement gives LGP access to some of the best in-class distribution services in Germany and potentially across Europe as the parties look to roll out these strains across the EU,” said Little Green Pharma CEO, Fleta Soloman.

“This is perfectly aligned with our longstanding strategy to gain market share in Europe, and also marks a significant turning point for the LGP Denmark facility, being the first in what we hope is a suite of high-volume purchase agreements.” 

In their last half-year report, LGP posted a revenue increase of 94% from $3.5m to 7.3m, where $7.2m is solely accounted for by the sales of medical cannabis. This significant increase is from a series of developments where the Company saw its products distributed to Germany, the United Kingdom, France, New Zealand, Brazil, Poland, Lithuania and Denmark. 

For the majority, LGP shares have been tracking down since reaching a high of $1.01 in February 2021, however, since then shares have fallen to a modest $0.45 at the time of writing. 

  • About
  • Latest Posts
Jack Cornips
Trading Desk Assistant at Emerald Financial
Latest posts by Jack Cornips (see all)
  • UNITH delivers eSocial Worker for public health services across 14 countries - December 5, 2023
  • Novatti cashing out of Reckon investment, clears debt to simplify payments business - November 17, 2023
  • Novatti seizes opportunity in Australia’s cashless transition as revenues rise while expenses drop - October 30, 2023
  •  
  •  
  •  
  •  
  • cannabis
  • cannabis healthcare
  • DEMECAN
  • Fleta Soloman
  • Germany
  • lgp
  • lgp asx
  • Little green pharma
  • medical cannabis
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Jack Cornips
Trading Desk Assistant at Emerald Financial
Latest posts by Jack Cornips (see all)
  • UNITH delivers eSocial Worker for public health services across 14 countries - December 5, 2023
  • Novatti cashing out of Reckon investment, clears debt to simplify payments business - November 17, 2023
  • Novatti seizes opportunity in Australia’s cashless transition as revenues rise while expenses drop - October 30, 2023

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Jack Cornips
Trading Desk Assistant at Emerald Financial
Latest posts by Jack Cornips (see all)
  • UNITH delivers eSocial Worker for public health services across 14 countries - December 5, 2023
  • Novatti cashing out of Reckon investment, clears debt to simplify payments business - November 17, 2023
  • Novatti seizes opportunity in Australia’s cashless transition as revenues rise while expenses drop - October 30, 2023
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.